CD274 and diffuse large B-cell lymphoma: Clinical trials for PD‐1/PD‐L1 blockade have shown some response in refractory and relapsed FL (40% ORR) and DLBCL (36%) but not as striking as in non‐GC‐derived classical Hodgkin lymphoma (87%).168, 218 A combinational approach with synergistic drugs to jointly target several immune evasion mechanisms would therefore likely be highly beneficial.